



HEMOPHILIA

Study Companion

ASH Abstracts Referenced

Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia a: Results of the Joint Outcome Continuation Study

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study

The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab

Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens

A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A

References

1. Koch JA. Haemophilia in the newborn. A case report and literature review. *S Afr Med J*. 1978;53(18):721-722.
2. Kavakli K, Kurugol Z, Goksen D, Nisli G. Should hemophiliac patients be circumcised? *Pediatr Hematol Oncol*. 2000;17(2):149-153.
3. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. *Blood*. 2007;109(11):4648-4654.
4. Rodriguez V, Titapiwatanakun R, Moir C, Schmidt KA, Pruthi RK. To circumcise or not to circumcise? Circumcision in patients with bleeding disorders. *Haemophilia*. 2010;16(2):272-276.
5. Goodeve AC. Advances in carrier detection in haemophilia. *Haemophilia*. 1998;4(4):358-364.
6. <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendation-Concerning-Prophylaxis>.
7. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. *N Engl J Med*. 2007;357(6):535-544.
8. Warren B, Thornhill D, Stein J, Fadell M, Funk S, Lane H. Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia a: Results of the Joint Outcome Continuation Study. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
9. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM, Group ES. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). *J Thromb Haemost*. 2011;9(4):700-710.
10. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. *Haemophilia*. 2001;7(4):392-396.



HEMOPHILIA

Study Companion

11. Recommendation on the Use and Management of Emicizumab-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors [press release]. December 6 2018.
12. Thornburg CD, Duncan NA. Treatment adherence in hemophilia. *Patient Prefer Adherence*. 2017;11:1677-1686.
13. Aldrige S. Hemophilia Summer Camps: Camps for children with hemophilia and other bleeding disorders. 2007; <https://hemaware.org/life/hemophilia-summer-camps>. Accessed January 19, 2019.
14. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. *Blood*. 2010;115(10):2057-2064.
15. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. *Blood*. 2012;119(3):666-672.
16. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. *Blood*. 2012;120(12):2405-2411.
17. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. *Thromb Res*. 2013;131 Suppl 2:S11-14.
18. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. *Blood*. 2011;118(10):2695-2701.
19. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. *N Engl J Med*. 2013;369(24):2313-2323.
20. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. *Blood*. 2016;127(14):1761-1769.
21. Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. *Blood*. 2014;124(26):3880-3886.
22. Graf L. Extended half-life factor VIII and factor IX preparations. *Transfus Med Hemother*. 2018;45(2):86-91.
23. Ragni MV, Kulkarni R, Pasi KJ, et al. B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B. Paper presented at: American Society of Hematology; December 1-4, 2018; San Diego.
24. Shapiro AD, Pasi KJ, Ozelo MC, et al. Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B. *Res Pract Thromb Haemost*. 2019;3(1):109-113.
25. Shapiro AD, Chaudhury A, Jain N, et al. Real-World Data on the Use of rFIXFc in Subjects With Hemophilia B for Up to 3.7 Years Demonstrates Improved Bleed Control and Adherence With Reduced Treatment Burden. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
26. Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia a. *Thromb Res*. 2018;168:20-27.
27. Kembell-Cook G, Tuddenham EG, Wacey AI. The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. *Nucleic Acids Res*. 1998;26(1):216-219.
28. ter Avest PC, Fischer K, Mancuso ME, et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. *J Thromb Haemost*. 2008;6(12):2048-2054.



HEMOPHILIA

Study Companion

29. NHFMaSAC. MASAC Recommendations on Standardized Testing and Surveillance for Inhibitors in Patients with Hemophilia A and B. 2015; <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-on-Standardized-Testing-and-Surveillance-for-Inhibitors-in-Patients-with-Hemophilia-A-and-B>. Accessed January 18, 2019.
30. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. *N Engl J Med*. 2016;374(21):2054-2064.
31. Liesner R, Versteden J, Lowndes S, Belyanskaya L, Oldenburg J, Pavlova A. Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
32. Young G, Liesner R, Sidonio R, et al. Efficacy of Efficacy of Efficacy Provides Flexible and Effective Bleed Control in Children with Hemophilia A with Inhibitors: Results from the HAVEN 2 Study. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
33. Batsuli G, Zimowski K, Tickle K, Meeks S, Sidonio R. The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Efficacy. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
34. NHFMaSAC. Recommendation on the Use and Management of Efficacy-kxwh (Hemlibra®) for Hemophilia A with and without Inhibitors. 2018; <https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Recommendation-on-the-Use-and-Management-of-Efficacy-kxwh-Hemlibra-for-Hemophilia-A-with-and-without-Inhibitors>. Accessed January 24, 2019.
35. Anderson A, Forsyth A. Playing It Safe – Bleeding Disorders, Sports and Exercise. 2017. https://www.hemophilia.org/sites/default/files/document/files/Playing-It-Safe_0.pdf. Accessed January 26, 2019.
36. Malec L, Witmer C, Jaffray J, et al. Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
37. Malec L, White G, Croteau S, Cheng G, Ragni MV. Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
38. Nichol M, Curtis R, Ding Y, et al. Impact of Prophylaxis Usage on Bleeding Rates Among Persons with Hemophilia A: Evidence from Longitudinal Analyses in the USA. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2019; San Diego.
39. Watt M, Epstein J, Xuan D. Personalization of Treatment Regimens for Active Patients: A Comparison of Hemophilia Prophylaxis Treatment Regimens. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2018; San Diego.
40. Schroeder C, Kallenbach F, Volland L, et al. "Hemophilia Vertical": Effects of therapeutic rock climbing on joint health in hemophilia patients with severe arthropathies. *Blood*. 2016;128:4754-4754.
41. Schroeder C, Barnes RF, Volland L, Nguyen S, Von Drygalski A. Effects of top rope climbing therapy on joint health in adult haemophilia patients with severe arthropathies. *J Haem Pract*. 2018;5(1).
42. Tiede A, Goldman G, Miljic P, et al. A New Dosing Model Based on Body Mass Index to Guide Factor VIII Dosing in Patients with Hemophilia A. Paper presented at: American Society of Hematology Annual Meeting; December 1-4, 2019, 2019; San Diego.



HEMOPHILIA

Study Companion